Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform.    Click the below to access the fill Forbes article.

Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems (forbes.com)

Link to Nature Communications publication on the PRV Platform is also provided below.

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer | Nature Communications

Media Contact: communicationteam@privotechnologies.com 

September 8, 2022

Share this post

Author

Related Posts

19Aug

Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

14Nov

Privo Technologies earns first ever runner-up placement at the Salisbury Award competition in Bethesda, Maryland.

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more

12Nov

Privo Technologies receives $3M Bridge Award from the National Cancer Institute (NCI).

​​​​​Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more

22Oct

Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma

PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more

13Sep

Privo receives Commercialization Award from the National Cancer Institute

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more

03Nov

Privo receives Orphan Designation from the Food and Drug Administration.

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more

01Apr

National Cancer Institute awards

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

10Dec

Privo Technologies receives 2015 TechConnect Innovation Award

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

20Aug

Privo Technologies, Inc. Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more

19Aug

Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition 2020

PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more

Contact Us
close slider

Contact Us